Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Champions Oncology (CSBR) Operating Leases (2019 - 2026)

Champions Oncology (CSBR) has 7 years of Operating Leases data on record, last reported at $4.2 million in Q3 2025.

  • For Q3 2025, Operating Leases changed N/A year-over-year to $4.2 million; the TTM value through Jul 2025 reached $4.2 million, changed N/A, while the annual FY2025 figure was $6.1 million, 0.2% changed from the prior year.
  • Operating Leases reached $4.2 million in Q3 2025 per CSBR's latest filing, down from $6.1 million in the prior quarter.
  • Across five years, Operating Leases topped out at $9.0 million in Q4 2022 and bottomed at $4.2 million in Q3 2025.
  • Average Operating Leases over 5 years is $7.2 million, with a median of $7.4 million recorded in 2023.
  • Peak YoY movement for Operating Leases: soared 6821.6% in 2021, then decreased 24.43% in 2023.
  • A 5-year view of Operating Leases shows it stood at $8.5 million in 2021, then increased by 5.16% to $9.0 million in 2022, then fell by 24.43% to $6.8 million in 2023, then dropped by 20.68% to $5.4 million in 2024, then decreased by 21.03% to $4.2 million in 2025.
  • Per Business Quant database, its latest 3 readings for Operating Leases were $4.2 million in Q3 2025, $6.1 million in Q2 2025, and $5.4 million in Q4 2024.